Junshi Biosciences (688180.SH) announced its semi-annual performance, with a net loss attributable to shareholders of 413 million yuan.

Wisdom Finance APP News, Junshi Biosciences (688180.SH) disclosed its 2025 interim report. During the reporting period, the company achieved a revenue of 1.168 billion yuan, a year-on-year increase of 48.64%; the net loss attributable to the parent company was 413 million yuan; the non-recurring net profit loss was 478 million yuan; and the basic earnings per share was -0.42 yuan.